tiprankstipranks
Trending News
More News >

Karyopharm backs 2023 revenue view $145M-$160M, consensus $151.17M

Continues to expect that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on KPTI:

Disclaimer & DisclosureReport an Issue